Despite sufficient antigenicity, the efficacy of PD-(L)1 inhibition may be undermined by the inadequate response of tumor cells to IFN-γ signaling and the tumor-intrinsic loss of MHC [11]. The gene discussed is HLA-C; the disease is neoplasm.